Identification and validation of a novel biologics target in triple negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Scientific reports, 9.2019, Nr. 1, Art. 14934, doi:10.1038/s41598-019-51453-w
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2019
- Urheber
-
Wali, Vikram B.
Patwardhan, Gauri A.
Pelekanou, Vasiliki
Karn, Thomas
Cao, Jian
Ocana, Alberto
Yan, Qin
Nelson, Bryce
Hatzis, Christos
Pusztai, Lajos
- URN
-
urn:nbn:de:hebis:30:3-551039
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:55 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wali, Vikram B.
- Patwardhan, Gauri A.
- Pelekanou, Vasiliki
- Karn, Thomas
- Cao, Jian
- Ocana, Alberto
- Yan, Qin
- Nelson, Bryce
- Hatzis, Christos
- Pusztai, Lajos
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2019
Ähnliche Objekte (12)
Target Identification and Validation of novel Lipid Storage Inhibitors
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
MicroRNA signatures in triple-negative breast cancer
Drug and therapy development for triple negative breast cancer
Identification and validation of ENTPD5 as a novel target gene of mutant p53 in cancer
Target identification and validation of natural products or synthetic compounds by activity-based protein profiling
Targeted therapies for the treatment of triple-negative breast cancer
Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers
Identifikation molekularer Targets für die Therapie des triple-negativen Mammakarzinoms
MiR-4646-5p acts as a tumor-suppressive factor in triple negative breast cancer and targets the cholesterol transport protein GRAMD1B
Target Identification of anti-mycobacterial Substances
Target Identification and Validation of novel Lipid Storage Inhibitors
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
MicroRNA signatures in triple-negative breast cancer
Drug and therapy development for triple negative breast cancer
Identification and validation of ENTPD5 as a novel target gene of mutant p53 in cancer
Target identification and validation of natural products or synthetic compounds by activity-based protein profiling
Targeted therapies for the treatment of triple-negative breast cancer
Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers
Identifikation molekularer Targets für die Therapie des triple-negativen Mammakarzinoms
MiR-4646-5p acts as a tumor-suppressive factor in triple negative breast cancer and targets the cholesterol transport protein GRAMD1B
Target Identification of anti-mycobacterial Substances
Target Identification and Validation of novel Lipid Storage Inhibitors
Target Identification and Validation in Ibrutinib-treated Mantle Cell Lymphoma
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
MicroRNA signatures in triple-negative breast cancer
Drug and therapy development for triple negative breast cancer
Identification and validation of ENTPD5 as a novel target gene of mutant p53 in cancer
Target identification and validation of natural products or synthetic compounds by activity-based protein profiling
Targeted therapies for the treatment of triple-negative breast cancer
Evaluation of SSEA-4 as a CAR T cell therapeutic target for the treatment of chemoresistant triple negative breast cancers
Identifikation molekularer Targets für die Therapie des triple-negativen Mammakarzinoms
MiR-4646-5p acts as a tumor-suppressive factor in triple negative breast cancer and targets the cholesterol transport protein GRAMD1B